Effect of galcanezumab on migraine headache days in women with menstrual migraine: A post hoc analysis

被引：0
|
作者：
MacGregor, E. [1 ]
Okonkwo, R. [2 ]
Fernandes, M. F. [2 ]
Rettiganti, M. [2 ]
Detke, H. [2 ]
Pavlovic, J. M. [3 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Montefiore Headache Ctr, Albert Einstein Coll Med, Bronx, NY USA
来源：
HEADACHE | 2021年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IOR-01
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [1] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of Phase 3 Placebo-Controlled Trials of Patients with Episodic and Chronic Migraine Treated with Galcanezumab
    Aurora, S.
    Ruff, D.
    Zhang, Q.
    Pearlman, E.
    HEADACHE, 2018, 58 : 163 - 163
  • [2] Factors associated with significant reduction in migraine headache days: a post hoc analysis of phase 3 placebo-controlled trials of patients with episodic and chronic migraine treated with galcanezumab
    Aurora, Sheena K.
    Ruff, Dustin D.
    Zhang, Qi
    Pearlman, Eric M.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [3] Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2
    Macgregor, E. Anne
    Okonkwo, Rose
    Detke, Holland C.
    Polavieja, Pepa
    Fernandes, Maria S.
    Pavlovic, Jelena M.
    HEADACHE, 2024, 64 (02): : 179 - 187
  • [4] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, Sheena
    Oakes, Tina
    Zhang, Qi
    Ahl, Jonna
    Martinez, James
    NEUROLOGY, 2017, 88
  • [5] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, Sheena
    Oakes, Tina
    Zhang, Qi
    Ahl, Jonna
    Martinez, James
    NEUROLOGY, 2017, 88
  • [6] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, S. K.
    Oakes, T. M.
    Zhang, Q.
    Ahl, J.
    Martinez, J. M.
    HEADACHE, 2017, 57 : 182 - 183
  • [7] A POST HOC ANALYSIS OF FACTORS ASSOCIATED WITH SIGNIFICANT REDUCTION IN MIGRAINE HEADACHE DAYS FROM THREE PHASE 3 PLACEBO-CONTROLLED TRIALS OF PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE TREATED WITH GALCANEZUMAB
    Aurora, S. K.
    Ruff, D. D.
    Zhang, Q.
    Pearlman, E. M.
    CEPHALALGIA, 2018, 38 : 81 - 82
  • [8] Headache and menstrual Migraine
    Wildt, L.
    GYNAKOLOGE, 2014, 47 (09): : 624 - 625
  • [9] Sustained Reduction of Migraine Headache Days in Patients with Episodic Migraine During Months 4 to 6 of Treatment with Galcanezumab
    Tepper, Stewart J.
    Ruff, Dustin
    Wietecha, Linda
    NEUROLOGY, 2020, 94 (15)
  • [10] Sustained Reduction of Migraine Headache Days in Patients With Episodic Migraine During Months 4 to 6 of Treatment With Galcanezumab
    Ferrari, Michel D.
    Tepper, Stewart J.
    Ruff, Dustin
    Wietecha, Linda
    CEPHALALGIA, 2019, 39 : 217 - 217
12345